Last Thursday I posted an entry discussing DOJ’s investigation of Big Pharma and the possibility that this probe is the result of a whistleblower. Since posting, we have been contacted by Mike Koehler at the FCPA Professor Blog who advised that parts of the Big Pharma investigation have been ongoing for years and are likely not the result of a Dodd-Frank whistleblower. Mr. Koehler’s blog offers considerable insight on the FCPA and his opinions are greatly appreciated.
Despite the fact that DOJ’s current Big Pharma investigation was not spurred by whistleblowers, it may very well receive help along the way from informed citizens. We at the Corporate Observer remain vigilant in our watch for new Dodd-Frank era whistleblowers. Be sure to check in for more whistleblower updates as they occur.